Detalhe da pesquisa
1.
Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study.
Eur J Haematol
; 107(4): 436-448, 2021 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-34139044
2.
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
Am J Hematol
; 98(8): E204-E208, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37222267
3.
Nilotinib induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia.
Am J Hematol
; 93(7): E162-E164, 2018 07.
Artigo
Inglês
| MEDLINE | ID: mdl-29633310
4.
Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment.
PLoS One
; 14(7): e0218444, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31318870
5.
Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment.
Cancer Biomark
; 21(1): 41-53, 2017 Dec 12.
Artigo
Inglês
| MEDLINE | ID: mdl-29036785